Biomarkers Associated with Clinical Activity of Pd-L1 Blockade in Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) in a Phase I Study of Mpdl3280A

  • Soria J
  • Gettinger S
  • Gordon M
  • et al.
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Aim: Cancers can evade immune surveillance by upregulating PD-L1. MPDL3280A, a human anti-PD-L1 mAb with an engineered Fc domain, blocks PD-L1 binding to its receptors PD-1 and B7.1 on activated T cells. Predictive factors of response to PD-L1 blockade are not well characterized. Here, we examine biomarkers that might predict MPDL3280A response.Methods: NSCLC pts received MPDL3280A 1-20 mg/kg IV q3w. Pts were treated for ≤ 1 y. Responses (ORR, including unconfirmed) were assessed by RECIST v1.1. FFPE tumor samples were analyzed by IHC and Genentech immunochip measuring 90 immune-related genes to characterize the tumor immune microenvironment at baseline. Tumor-infiltrating immune cells (ICs) or tumor cells (TCs) were scored as IHC 0, 1, 2 or 3 if < 1%, ≥ 1% but < 5%, ≥ 5% but < 10%, or ≥ 10% of cells expressed PD-L1, respectively. Positivity for PD-L2, IDO1, LAG3, TIM3, CTLA4, B7-H3 and B7-H4 was by gene expression ≥ median.Results: As of Apr 30, 2013, 53 NSCLC pts dosed by Oct 1, 2012, were evaluable for efficacy. In this trial ≈ 30% of NSCLC pts were PD-L1 IHC 2 or 3. ORRs were associated with PD-L1 expression in ICs (p = .02): IHC 3: ORR 83% (5/6), IHC 2: 14% (1/7), IHC 1: 15% (2/13), IHC 0: 20% (4/20). PD-L1 expression in TCs did not significantly correlate with response (p = .92). The 24-wk PFS rate was 45%. Expression of checkpoint markers was a weaker predictor of MPDL3280A response and did not appear to confer MPDL3280A resistance in PD-L1 IHC2/3 pts (Table). Additionally, elevated IFNγ expression, and IFNγ-inducible genes (e.g., IDO1 and CXCL9), did not appear to associate with MPDL3280A response.a For pts with both PD-L1 IHC and immunochip data only (N = 37). b PD-L1 IHC scores based on ICs.Response Rates in Biomarker-Defined Subpopulationsa,bConclusions: These data suggest PD-L1 expression has a stronger correlation with ORR compared to other immune checkpoints. PD-L1 appears to be a leading predictive biomarker for response to MPDL3280A. These findings help provide a better understanding of biomarkers and MPDL3280A clinical activity.Disclosure: J-C. Soria has received honoraria from Roche/Genentech; M. Gordon has served as an advisor/consultant to and has received research funding from Roche/Genentech; R.S. Heist has received clinical research funding to her institution from Roche, GSK, EMD Serono, Exelixis and Debiopharm; L. Horn: Research funding from Astellas. Served as an adviser for Bristol Myers Squibb, Clovis, Helix bio (compensated) and PUMA, Xcovery (uncompensated). Steering Committee: Bayer (Uncompensated). Received honoraria from Boehringer Ingelheim; D.R. Spigel has served in an uncompensated role as advisor to Genentech; M. Kowanetz, A. Mokatrin, Y. Xiao and A. Sandler: is an employee of Genentech, Inc.; E. Felip has served as an advisor to BI, Novartis, Roche, BMS and Eli Lilly. All other authors have declared no conflicts of interest.

Cite

CITATION STYLE

APA

Soria, J.-C., Gettinger, S., Gordon, M., Heist, R. S., Horn, L., Spigel, D. R., … Felip, E. (2014). Biomarkers Associated with Clinical Activity of Pd-L1 Blockade in Non-Small Cell Lung Cancer (Nsclc) Patients (Pts) in a Phase I Study of Mpdl3280A. Annals of Oncology, 25, iv465. https://doi.org/10.1093/annonc/mdu349.101

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free